Figure 6.

Kaplan–Meier survival analysis of subgroup analysis with regard to BCLC stage. (A) In intermediate stage patients, significantly longer RFS was observed in low TNR_FDG. (B) In advanced stage patients, significantly longer RFS was observed in low FAratio. Multivariate analysis revealed in intermediate stage patients that TNR_FDG was the only significant factor and in advanced stage patients, and FAratio was the only significant factor in the prediction of tumor progression after TACE. BCLC = Barcelona Clinic Liver Cancer, FAratio = ratio of TNR_FDG and TNR_Ace, TACE = transarterial chemoembolization, TNR_FDG = maximum tumor SUV to mean normal liver SUV ratio of ¹⁸F-FDG, RFS = recurrence-free survival.